一种用于女性性功能障碍的新型非药物真空疗法。

A new non-pharmacological vacuum therapy for female sexual dysfunction.

作者信息

Billups K L, Berman L, Berman J, Metz M E, Glennon M E, Goldstein I

机构信息

University of Minnesota, Minneapolis, Minnesota, USA.

出版信息

J Sex Marital Ther. 2001 Oct-Dec;27(5):435-41. doi: 10.1080/713846826.

DOI:10.1080/713846826

PMID:11554204

Abstract

Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

摘要

尽管女性性功能障碍（FSD）影响着40%的美国女性，但尚无美国食品药品监督管理局（FDA）批准的药物治疗方法。EROS-CTD（阴蒂治疗设备，UroMetrics公司，明尼苏达州圣保罗）治疗是FDA批准上市的首个针对FSD的治疗方法。阴蒂充血被认为在女性性唤起和总体性满意度中起着重要作用。EROS-CTD是一种小型的、由电池供电的设备，旨在增强阴蒂充血，增加阴蒂的血流量，并最终改善患有FSD的女性的性唤起。本研究的目的是评估EROS-CTD对正常志愿者和患有FSD的女性的性唤起（生殖器感觉、阴道润滑、达到性高潮的能力和性满意度）的有效性。